Neurothera Labs Inc.
About
Neurothera Labs is a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders. The Company is developing proprietary cannabinoid-based pharmaceuticals intended to increase patients’ safety by reducing doses while maintaining effectiveness.
The Company
Backed by an advancing clinical pipeline, a growing IP portfolio, and strategic collaborations, Neurothera Labs continues to expand its reach in CNS-focused drug development.
stages
IP portfolio
Leadership
CEO
Oz Adler
Experience in managerial, financial, tax and accounting practices. From 2012 to 2017, employed as a certified public accountant at Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global. B.A. in Accounting and Business Management from the College of Management, Israel.
CFO
Gabriel Kabazo
Finance and operations professional with over 25 years of experience supporting accounting, financing and IT operations in complex corporate settings. Since July 2025, CEO of Fort Technology Inc. (TSXV: FORT). Since May 2020, CFO of Femto Technologies Inc. (OTCID: FMTOF). Since July 2022, CFO of Plantify Foods, Inc. (TSXV: PTFY). Since January 2022, CFO of Starmet Ventures Inc. Since September 2025, CFO of TempraMed Technologies Ltd. (CSE: VIVI). Previously CFO of m-Wise Inc. (2002–2011) and Controller of On Track Innovations Ltd. (2000–2002). B.A. in Accounting & Economics from Tel Aviv University (1997); C.P.A. (Israel) 1999; MBA (Finance) from the University of British Columbia, Sauder School of Business (2006).
CTO
Dr. Adi Zuloff-Shani, PhD
R&D professional with about 20 years of experience in the biotech and healthcare industry. Has brought two products from bench to market: an immuno-cell-based product and a food supplement. Currently leading development of several pharmaceutical products designated for the U.S., EU and Israeli markets. Experience in research and development, manufacturing, clinical and regulatory affairs. Ph.D. in human biology and immunology from Bar-Ilan University, Israel.
Chairman
Itschak Shrem
More than 40 years of experience in financial markets and venture capital. Founded Dovrat Shrem Ltd. in 1991. Previously spent 15 years at Clal Israel Ltd., including as chief operating officer, responsible for capital markets and insurance businesses. In 1993 founded Pitango Venture Capital Fund (formerly Polaris) and served as a partner of Pitango Funds I, II and III. Managing Director of Yaad Consulting 1995 Ltd. since 1995. Currently a director of Rail Visions Ltd. Previous boards include Tel Aviv Sourasky Medical Center, the Weizmann Institute, Eden Spring Ltd., Nano Dimension Ltd., Ormat Industries Ltd., Retalix Ltd., and chairman of Sphera Funds Management Ltd. B.A. in Economics and Accounting from Bar-Ilan University; M.B.A. from Tel Aviv University.